32 65

Cited 0 times in

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김명진-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박미숙-
dc.contributor.author박준용-
dc.contributor.author백송이-
dc.contributor.author안상훈-
dc.contributor.author이형진-
dc.contributor.author정용은-
dc.contributor.author최홍준-
dc.contributor.author한광협-
dc.contributor.author이재승-
dc.date.accessioned2020-12-11T08:00:35Z-
dc.date.available2020-12-11T08:00:35Z-
dc.date.issued2020-11-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180742-
dc.description.abstractBackground/aims: The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria have been used to assess treatment responses for hepatocellular carcinoma (HCC) patients. We investigated which criteria provides better survival predictions in HCC patients treated with transarterial radioembolization (TARE). Methods: In total, 102 patients with unresectable intrahepatic HCC, who were treated with TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after TARE was evaluated at 1, 3, and 6 months by the mRECIST and RECIST 1.1. Responders were defined as patients with complete or partial responses by each criterion. Results: The median age of 83 men and 19 women was 64.3 years. The median alpha-fetoprotein and des-gamma-carboxy prothrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, respectively. The median maximal tumor size was 8.3 cm, and multiple tumors were observed in 36 patients (35.3%). During the follow-up period (median, 20.7 months), 21 patients (20.6%) died, with a mean survival time of 55.5 months. The cumulative survival rate was 96.1% at 6 months and 89.3% at 12 months. Responders, defined by the mRECIST at 1, 3, and 6 months after TARE, showed better survival outcomes than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, p=0.061 at 6 months). The survival rates of responders and nonresponders defined by the RECIST 1.1 were similar (all p>0.05). Conclusions: Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherEditorial Office of Gut and Liver-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleThe Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHong Jun Choi-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSong-Ee Baek-
dc.contributor.googleauthorYong Eun Chung-
dc.contributor.googleauthorMi-Suk Park-
dc.contributor.googleauthorMyeong-Jin Kim-
dc.contributor.googleauthorHyungjin Rhee-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.5009/gnl19197-
dc.contributor.localIdA00385-
dc.contributor.localIdA00426-
dc.contributor.localIdA00426-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA01463-
dc.contributor.localIdA01463-
dc.contributor.localIdA01675-
dc.contributor.localIdA01675-
dc.contributor.localIdA01822-
dc.contributor.localIdA01822-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.contributor.localIdA05171-
dc.contributor.localIdA05171-
dc.contributor.localIdA03662-
dc.contributor.localIdA03662-
dc.contributor.localIdA05990-
dc.contributor.localIdA05990-
dc.contributor.localIdA04268-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid32050313-
dc.subject.keywordCarcinoma-
dc.subject.keywordEmbolization-
dc.subject.keywordRadiotherapy-
dc.subject.keywordResponse Evaluation Criteria in Solid Tumors-
dc.subject.keywordTreatment outcome-
dc.subject.keywordhepatocellular-
dc.subject.keywordtherapeutics-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김명진-
dc.contributor.affiliatedAuthor김명진-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박미숙-
dc.contributor.affiliatedAuthor박미숙-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor백송이-
dc.contributor.affiliatedAuthor백송이-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이형진-
dc.contributor.affiliatedAuthor이형진-
dc.contributor.affiliatedAuthor정용은-
dc.contributor.affiliatedAuthor정용은-
dc.contributor.affiliatedAuthor최홍준-
dc.contributor.affiliatedAuthor최홍준-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume14-
dc.citation.number6-
dc.citation.startPage765-
dc.citation.endPage774-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.14(6) : 765-774, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.